Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
24.88
+0.04 (0.16%)
At close: May 29, 2026, 4:00 PM EDT
25.37
+0.49 (1.97%)
After-hours: May 29, 2026, 4:44 PM EDT
Damora Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Damora Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $43.14. The average 1-year stock price forecast is 73.39% higher than the current stock price, while the lowest is $35 (+40.68%) and the highest is $51 (+104.98%).
Price Target: $43.14 (+73.39%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Damora Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 4 | 5 | 5 | 6 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 4 | 5 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $35 | Buy | Initiates | $35 | +40.68% | May 28, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $45 | Buy | Maintains | $45 | +80.87% | May 17, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $55 → $51 | Buy | Maintains | $55 → $51 | +104.98% | May 15, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $40 | Buy | Maintains | $40 | +60.77% | May 13, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $40 | Buy | Reiterates | $40 | +60.77% | Apr 29, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.55
from -153.95
EPS Next Year
-2.17
from -1.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.00 | -1.75 | |
| Avg | -1.55 | -2.17 | |
| Low | -2.27 | -2.34 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.